Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
GlobalData on MSN4d
J&J’s Spravato receives FDA label expansion for depression monotherapyThe FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback